Overview

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Rush University Medical Center
Collaborator:
Eli Lilly and Company
Treatments:
Metformin
Olanzapine